-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Invitation to the grand event2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 10, 2021 /Medicine news eMedClub News/--On June 8, 2021, Bayer's BlueRock Therapeutics announced that its dopaminergic neuron drug DA01 derived from pluripotent stem cells for Parkinson's disease has completed its first administration and entered 1 Phase of clinical safety and tolerability research phase
.
At the same time, Asklepios BioPharmaceutical (AskBio), another Bayer company, has also promoted a gene therapy research program that also aims to provide cutting-edge treatments for Parkinson's disease
.
The project is currently in the phase 1b clinical research phase and is recruiting and evaluating patients to evaluate the safety and preliminary efficacy of the drug
.
Parkinson's disease is the most common neurodegenerative movement disorder, affecting more than 10 million people worldwide
.
It is caused by the damage of nerve cells (neurons) in the brain, which leads to a decrease in the level of dopamine (a neurotransmitter involved in memory or exercise processes).
The most important and debilitating symptom is the progress of motor control.
Sexual loss
.
Usually the early symptom of this disease is a tremor in one hand
.
Other symptoms include stiffness, cramps, and dyskinesias (involuntary, unstable, writhing movements of the face, arms, legs, or trunk)
.
At present, dopamine substitutes (such as levodopa) are commonly used to reduce the symptoms of the disease, but their effect will be weakened as the disease progresses.
There is currently no available therapy that can fully alleviate the disease
.
Bayer hopes that the Parkinson's stem cell + gene therapy pioneered by its company can change this situation, and fully understand the root cause of this destructive disease, and achieve treatment results beyond symptomatic treatment
.
Bayer believes in the bright prospects of gene and stem cell therapy, so it has invested heavily in these two projects in the past few years
.
Recommended reading: Bayer launches cell and gene therapy platform and officially enters the therapeutic fieldYimai Meng broke the news that Bayer Cell and Gene Therapy Head Wolfram Carius said: "The beginning of clinical trials represents the beginning of a truly breakthrough treatment option, BlueRock And AskBio’s clinical drug candidates may have great potential to treat Parkinson’s disease and can truly help patients meet their highly unmet medical needs
.
We are still in the early stages of clinical trials, but we are passionately committed to advancing breakthrough science To improve the lives of patients who have been waiting for innovative treatments for too long
.
”For more details, click on the QR code to read the reference materials in full: 1.
https:// cell-and-gene-therapies-for-parkinson-s-disease-/?keywords=bayer2.
https:// land-clinic3.
https://endpts.
com/incyte-faces-delay-on-fdas-jakafi-decision-for-cgvhd-bayers-parkinsons-cell-therapy-enters-the-clinic/ Original news reports on cutting-edge technologies, industry trends, and industry insights of innovative drugs, with over 160,000 users of all-media high-end matrix users, of which over 50% are industrial users, approximately 30% are scientific research and clinical users, and over 5% are users of investment institutions
.
In
order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
.
At the same time, Asklepios BioPharmaceutical (AskBio), another Bayer company, has also promoted a gene therapy research program that also aims to provide cutting-edge treatments for Parkinson's disease
.
The project is currently in the phase 1b clinical research phase and is recruiting and evaluating patients to evaluate the safety and preliminary efficacy of the drug
.
Parkinson's disease is the most common neurodegenerative movement disorder, affecting more than 10 million people worldwide
.
It is caused by the damage of nerve cells (neurons) in the brain, which leads to a decrease in the level of dopamine (a neurotransmitter involved in memory or exercise processes).
The most important and debilitating symptom is the progress of motor control.
Sexual loss
.
Usually the early symptom of this disease is a tremor in one hand
.
Other symptoms include stiffness, cramps, and dyskinesias (involuntary, unstable, writhing movements of the face, arms, legs, or trunk)
.
At present, dopamine substitutes (such as levodopa) are commonly used to reduce the symptoms of the disease, but their effect will be weakened as the disease progresses.
There is currently no available therapy that can fully alleviate the disease
.
Bayer hopes that the Parkinson's stem cell + gene therapy pioneered by its company can change this situation, and fully understand the root cause of this destructive disease, and achieve treatment results beyond symptomatic treatment
.
Bayer believes in the bright prospects of gene and stem cell therapy, so it has invested heavily in these two projects in the past few years
.
Recommended reading: Bayer launches cell and gene therapy platform and officially enters the therapeutic fieldYimai Meng broke the news that Bayer Cell and Gene Therapy Head Wolfram Carius said: "The beginning of clinical trials represents the beginning of a truly breakthrough treatment option, BlueRock And AskBio’s clinical drug candidates may have great potential to treat Parkinson’s disease and can truly help patients meet their highly unmet medical needs
.
We are still in the early stages of clinical trials, but we are passionately committed to advancing breakthrough science To improve the lives of patients who have been waiting for innovative treatments for too long
.
”For more details, click on the QR code to read the reference materials in full: 1.
https:// cell-and-gene-therapies-for-parkinson-s-disease-/?keywords=bayer2.
https:// land-clinic3.
https://endpts.
com/incyte-faces-delay-on-fdas-jakafi-decision-for-cgvhd-bayers-parkinsons-cell-therapy-enters-the-clinic/ Original news reports on cutting-edge technologies, industry trends, and industry insights of innovative drugs, with over 160,000 users of all-media high-end matrix users, of which over 50% are industrial users, approximately 30% are scientific research and clinical users, and over 5% are users of investment institutions
.
In
order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
